Immix Biopharma, Inc.

Immix Biopharma, Inc. reported a net loss of $29.4 million for the fiscal year ended December 31, 2025, compared to a net loss of $21.7 million in the prior year. The increased loss was driven by higher operating expenses, which rose to $30.0 million from $22.7 million, primarily due to increased research and development and general and administrative costs. The company ended the year with a strong liquidity position, with cash, cash equivalents, and short-term investments totaling $100.4 million, a significant increase from $17.7 million at the end of 2024, bolstered by equity financings including a public offering in December 2025 that generated net proceeds of approximately $93.7 million. Management believes existing cash resources and expected disbursements from a CIRM grant will fund operations for at least the next 12 months. The accumulated deficit increased to $104.5 million as of December 31, 2025.

Key Takeaways